AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MDWD

Hess Shmuel sold $75K of MDWD

Hess Shmuel (COO & Chief Commercial Officer) sold 5,823 shares of MediWound Ltd. (MDWD) at an average of $12.95 ($12.72–$13.13) across 3 trades over 2026-08-26 to 2026-08-27.

Original reporting
SEC EDGAR · Hess Shmuel
Published Aug 28, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDWD
Neutral
medium confidence
Mentioned
$MDWD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDWDNeutralLow
01

Why it matters

The filing provides the first public disclosure of the insider's complete exit from MDWD.

02

Market read

Minor impact expected due to small transaction size; primarily of interest to insider‑tracking traders.

03

What to watch

If the insider holds other positions or options, the sale may not reflect outlook.

Relevance 3/10Novelty 4/10Timing: filed Aug 28 2026

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$MDWDNeutralMedium confidence
Context

SEC Form 4 shows COO Hess Shmuel sold all 5,823 shares for $75,394, reducing his stake to zero.

Expected impact

Potential slight downward pressure, unlikely to move price materially.

Evidence & confidence

Sale is small relative to market cap; market may view it as routine rather than a red flag.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be unrelated personal liquidity need; not a bearish signal.

Key entities

  • Company
    MediWound Ltd.

    Biotech firm listed on the OTC market under MDWD.

  • Insider
    Hess Shmuel

    Chief Operating Officer and Chief Commercial Officer of MediWound.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDWD insider trading history →

Related articles

$MDWDMed

A sale of 1.2 million MediWound shares is expected to close around Nov. 5.

MediWound (MDWD) announced a share sale of 1.2 million ordinary shares, with H.C. Wainwright & Co. as underwriter. The deal is expected to close around Nov. 5, 2026, with gross proceeds estimated at approximately $30 million, assuming no exercise of the underwriter’s option. The company plans to use the net proceeds for working capital and general corporate purposes.

stocktitan.net
$MDWDHighAI 8/10

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)

MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.

investegate.co.uk
$MDWDMed

MediWound Ltd. (MDWD): Financial results for Q2 2026

MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it

SEC EDGAR 6-K